Hot Topics in Heart Failure: New Data and Therapies That Are Changing the Treatment Landscape

Hear these expert faculty as they discuss questions such as, “Do outcomes from DAPA-HF and EMPEROR-Reduced suggest a class effect of SGLT2 inhibitors?” “Is it safe to start ARNI in the hospital, and does it influence post discharge outcomes?” “What is the likely place of emerging therapies like vericiguat and omecamtiv mecarbil in HFrEF?”

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC Javed Butler, MD, MPH, MBA Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: December 15, 2020 Expired: December 14, 2021

New and Emerging Treatments

The Place of SGLT2 Inhibitors

Question and Answer Session